Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Kidney Cancer Clinical Trials

A listing of Kidney Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (289) clinical trials

Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury

This study will investigate possible renoprotective effects of DPP4 inhibitor on cisplatin induced acute kidney injury.

Phase

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

This is a phase 1, single site, open label and non-randomized study to evaluate the safety of PEG-BCT-100. Patient enrollment and sample size will follow a classical 3 + 3 dose-escalation design. The study will enroll a maximum of 36 patients. Cohorts of 3 patients will receive an initial single ...

Phase

A Phase 1 Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma

PART 1: This is a Phase 1, multiple-dose, dose-escalation trial of PT2385 Tablets, where patients with advanced ccRCC will be assigned to sequential dose cohorts. Patient safety will be monitored with frequent physical examinations, vital sign measurements, electrocardiograms (ECGs), and hematology and chemistry laboratory studies, and by recording all adverse ...

Phase

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

All patients will receive IL-2 at 600,000 international units per kilogram (kg) by intraveneous bolus (IVB) every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles. Patients assigned to SBRT arm ...

Phase

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Varlilumab is a fully human monoclonal antibody that binds to a molecule called CD27 found on certain immune cells and may act to promote anti-tumor effects. Nivolumab is a fully human monoclonal antibody that binds to a molecule called PD-1 on immune cells and promotes anti-tumor effects. Eligible patients that ...

Phase

Patients are needed to participate in a clinical research study for the treatment of Malignant neoplasm of kidney, Urologic Malignant Disorders

Background Disorders under investigation are: Autosomal dominant inherited urologic malignant disorders including: von Hippel- Lindau (VHL), hereditary papillary renal cancer (HPRC), Birt Hogg Dube (BHD) and hereditary leiomyomatosis and renal cell acarcinoma (HLRCC) as well as familial renal cancer. Studies have led to the identification and characterization of the VHL, ...

Phase N/A

Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

OBJECTIVES: - Determine the antitumor effect of allogeneic peripheral blood stem cell transplantation (PBSCT) in patients with metastatic renal cell carcinoma. - Evaluate the safety and toxicity of a nonmyeloablative, low-intensity, preparative regimen followed by an HLA-matched allogeneic PBSCT in these patients. - Determine engraftment by measuring donor-recipient chimerism in ...

Phase

Genetic Study of Patients With Inherited Urologic Malignancies

OBJECTIVES: - Characterize the natural and clinical histories of patients with inherited urologic malignancies. - Determine the genetic etiology of inherited urologic malignancies in which the gene defect is unknown, using linkage analysis, positional cloning, and evaluation of candidate genes. - Correlate specific mutations and associated protein domains with disease ...

Phase N/A

Collection of Blood Bone Marrow Tumor or Tissue Samples From Patients With Cancer to Study Drug Resistance

Background Ongoing research in the Experimental and Molecular Therapeutics Sections, NCI, requires the availability of blood, serum, tumor, hair follicle and tissue samples from patients with cancer. Resistance is the underlying cause of treatment failure, and may present as acquired or intrinsic drug resistance. Patients with cancer frequently present with ...

Phase N/A

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Background Kidney, prostate, bladder, testis and penile cancer account for 22% of cancers diagnosed in the United States and are responsible for 10% of cancer deaths each year in the U.S. Understanding the genes and gene pathways that cause genitourinary malignancies will provide the foundation for the development of targeted ...

Phase N/A